ArticleJournal of inflammation research2025
Prognostic Significance of C-Reactive Protein to Albumin Ratio in Predicting Long-Term Mortality Among Patients with Acute Heart Failure.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- C-reactive protein-to-albumin ratio and the mortality of patients with heart failure: a meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- The C-Reactive Protein/Albumin Ratio Predicts In-Hospital Mortality Across Age Groups.Nutrients · 2026Article
- Prognostic Role of High-Sensitivity C-Reactive Protein/Albumin Ratio in Heart Failure Patients.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Acute heart failure (AHF) is a prevalent cardiovascular condition. C-reactive protein (CRP) and low albumin levels are established significant prognostic markers in AHF. This study aimed to evaluate the prognostic value of the C-reactive protein to albumin ratio (CAR) for predicting long-term all-cause mortality in patients with AHF. In this study, AHF was defined as either newly diagnosed decompensated heart failure (HF) or an exacerbation of chronic compensated HF requiring hospitalization. The enrolled AHF patients encompassed the entire spectrum of ejection fractions. Methods: This single-center, retrospective study enrolled a total of 227 patients. Participants were categorized into two groups: a high CAR group (n = 96) and a low CAR group (n = 131). The study endpoints were all-cause mortality, cardiac mortality, and non-cardiac mortality after admission for AHF. Results: The follow-up period was 46 months. Patients with an elevated CAR exhibited significantly higher rates of all-cause mortality and cardiac mortality compared to those with lower CAR levels (49% vs 13%, P < 0.001 and 39.6% vs 7.6%, P < 0.001, respectively). The areas under the curve (AUC) for predicting all-cause mortality were 0.78 (95% CI: 0.713-0.841; p < 0.001) for CAR and 0.76 (95% CI: 0.695-0.826; p < 0.001) for NT-proBNP. Kaplan-Meier survival analysis demonstrated a significantly increased risk of all-cause mortality in patients with elevated CAR or NT-proBNP levels (Log rank test, p < 0.001 for both). Multivariate Cox regression analysis identified CAR as an independent predictor of all-cause mortality (hazard ratio [HR]: 1.043; 95% CI: 1.011-1.047; p = 0.008). Conclusion: The CAR is an independent predictor of long-term all-cause mortality in patients with AHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.